Therapy News and Research

RSS

UNC1215 chemical probe can help investigate L3MBTL3 methyl-lysine reader domain

In an article published as the cover story of the March 2013 issue of Nature Chemical Biology, Lindsey James, PhD, research assistant professor in the lab of Stephen Frye, Fred Eshelman Distinguished Professor in the UNC School of Pharmacy and member of the UNC Lineberger Comprehensive Cancer Center, announced the discovery of a chemical probe that can be used to investigate the L3MBTL3 methyl-lysine reader domain.

3 Mar 2013

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

New research in the Journal of Clinical Investigation reveals that tumours in melanoma patients deliberately create conditions that knock out the body's 'premier' immune defence and instead attract a weaker immune response unable to kill off the tumour's cancerous cells.

2 Mar 2013

Elekta launches Versa HD system to treat cancers

During a live global event, Elekta announced the launch of Versa HD, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers.

From Elekta 2 Mar 2013

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.

2 Mar 2013

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

Tiny particles filled with a drug could be a new tool for treating cancer in the future. A new study published by Swedish scientists in Particle & Particle Systems Characterization shows how such nanoparticles can be combined to secure the effective delivery of cancer drugs to tumour cells - and how they can be given properties to make them visible in MR scanners and thus rendered trackable.

1 Mar 2013

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.

1 Mar 2013

Scientists take important step toward designing a uniform protocol for microbiome research

Earth Day may be more than a month away, but another, more personal, ecosystem has been shown to also be worth protecting-within our bodies are communities of microbes that affect the behavior of human cells hosting them.

1 Mar 2013

Oraya Therapy safe and effective for patients with wet AMD

Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.

1 Mar 2013

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).

1 Mar 2013

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

At the Faculty of Pharmacy of the Basque Public University (UPV/EHU) the Pharmacokinetics, Nanotechnology and Gene Therapy research team is using nanotechnology to develop new formulations that can be applied to drugs and gene therapy.

1 Mar 2013

Stem cell line could also advance research into liver cancers, cystic fibrosis

Chronic or acute, liver failure can be deadly. Toxins take over, the skin turns yellow and higher brain function slows. "There is no effective therapy at the moment to deal with the toxins that build up in your body," said Neil Talbot, a Research Animal Scientist for the USDA Agricultural Research Service. "Their only option now is to transplant a liver."

1 Mar 2013

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial.

28 Feb 2013

U-M to study how exercise, other therapies might work differently in lean and obese individuals

Researchers at the University of Michigan School of Kinesiology have received a $1 million grant to study how exercise and other therapies might work differently in lean and obese individuals.

28 Feb 2013

Blocking aPKC activity can stop growth of transplanted skin tumors resistant to vismodegib

Hailed as a major step forward in the effort to develop targeted cancer therapies, a recently approved drug for the most common type of skin cancer has been a mixed blessing for patients. Although the initial response is usually dramatic, the tumors often recur as the cancer becomes resistant to treatment.

28 Feb 2013

Therapy News and Research

UNC1215 chemical probe can help investigate L3MBTL3 methyl-lysine reader domain

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

Elekta launches Versa HD system to treat cancers

PDL BioPharma fourth quarter total revenues increase to $86.0 million

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Scientists take important step toward designing a uniform protocol for microbiome research

Oraya Therapy safe and effective for patients with wet AMD

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

UPV/EHU team uses lipid nanoparticles to develop new formulations for drug delivery

Stem cell line could also advance research into liver cancers, cystic fibrosis

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

U-M to study how exercise, other therapies might work differently in lean and obese individuals

Blocking aPKC activity can stop growth of transplanted skin tumors resistant to vismodegib

Radiation, surgery offer best survival possibilities for metastatic gastric cancer patients

First study ever to analyze 25 years of data after radiation therapy for prostate cancer patients

GLP-1 pancreatitis concerns justified

Fatigue before cancer treatment impacts fatigue afterwards

Orofacial treatment beneficial for headache plus temporomandibular disorder

DDR may help decrease cognitive and physical effects of multiple sclerosis

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News